2021 INVESTOR MATERIALS

ANNUAL REPORT

View an enhanced version of our
Annual Report.

PROXY STATEMENT

View an enhanced version of our
Proxy Statement.

* Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.

Vote Online 

Your vote is IMPORTANT!

Please vote your proxy online now or by phone by dialing 855-673-0643.

Annual Meeting

Date

June 2, 2021

Time

8:00 AM EDT

Virtual Meeting

To Register for the Meeting



Deadline to Register*
May 31, 2021 
5:00 PM EDT

*Note: You must register by the deadline to be eligible to participate in the meeting.

About Us 


Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression.

Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Our integrated epigenetics platform includes a deep understanding of the biological context in which epigenetic regulatory proteins, or epigenetic regulators, operate, the development of small-molecule product candidates that selectively modulate their activity and the design of clinical development programs supported by novel biomarker strategies.

We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.